Videlis Nduba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Videlis Nduba has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Lilian Nkirote Njagi
Centre for Respiratory Diseases Research, Kenya Medical Research Institute , Nairobi
3 shared publications Aiban Ronoh
Affiliation National TB, Leprosy and Lung Disease Programme, Ministry of Health, Nairobi, Kenya
2 shared publications- Cheryl Kerama
Centre for Respiratory Diseases Research, Kenya Medical Research Institute (CRDR-KEMRI), Past Government Chemist, Opposite Diabetes Clinic. Nairobi-Kenya
2 shared publications - David J. Horne
Department of Medicine, Division of Pulmonary, Critical Care & Sleep Medicine; University of Washington; Seattle Washington USA
2 shared publications Dickson Kirathe
Affiliation National TB, Leprosy and Lung Disease Programme, Ministry of Health, Nairobi, Kenya
2 shared publicationsErick Nyadimo
Affiliation Centre for Respiratory Diseases Research, Kenya Medical Research Institute, Nairobi, Kenya
2 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
A Whole-blood Transcriptional Signature Associated With Obstructive Post-tuberculosis Lung Disease
Background: Post-tuberculosis (TB) lung disease (PTLD) affects ∼50% of persons with pulmonary TB (PTB). We recently discovered whole blood transcriptional signatures associated with PTLD. We examined whether a minimum gene signature predicts PTLD as a clinically useful biomarker. Methods: We prospectively enrolled 301 treatment naive adults with newly diagnosed PTB (cohort A). We collected whole blood at 0 and 6-month visits, isolated RNA, and measured a modified MTB host response (HR) signature (mHR) based on expression of DUSP3, GBP5, and TMBIM6. We recorded spirometry at 6 (n = 216) and 12 months (n = 210) after treatment initiation and examined the association of the mHR score with PTLD and Mtb aerosolization. We recruited household contacts of cohort A to compare mHR score with non-PTB participants (cohort B). Results: mHR was associated with TB (P = 4.15e−66) when compared to HHCs, treatment response (P = 1.07e−53), and characteristics including CD4 count (P = .003), bacillary load (P = 3.02e−05), lung cavities (P = 1.59e−04), and lung quadrants involved (P = 3.87e−06). The mHR score was not associated with Mtb aerosolization. In total, 105 (50%) participants had PTLD at 12 months including 61 with restriction, 26 with obstruction, and 18 with mixed obstruction and restriction. Baseline mHR was associated with obstructive PTLD at both 6 (P = .003) and 12 months (P = .012) in bivariate and multivariate analyses. The mHR score was not associated with restrictive lung disease. Conclusions: Baseline mHR was associated with obstructive PTLD at 6 and 12 months and may have applications in targeting treatment and prognostication.
- 29 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Open AccessA Whole-blood Transcriptional Signature Associated With Obstructive Post-tuberculosis Lung Disease
Background: Post-tuberculosis (TB) lung disease (PTLD) affects ∼50% of persons with pulmonary TB (PTB). We recently discovered whole blood transcriptional signatures associated with PTLD. We examined whether a minimum gene signature predicts PTLD as a clinically useful biomarker. Methods: We prospectively enrolled 301 treatment naive adults with newly diagnosed PTB (cohort A). We collected whole blood at 0 and 6-month visits, isolated RNA, and measured a modified MTB host response (HR) signature (mHR) based on expression of DUSP3, GBP5, and TMBIM6. We recorded spirometry at 6 (n = 216) and 12 months (n = 210) after treatment initiation and examined the association of the mHR score with PTLD and Mtb aerosolization. We recruited household contacts of cohort A to compare mHR score with non-PTB participants (cohort B). Results: mHR was associated with TB (P = 4.15e−66) when compared to HHCs, treatment response (P = 1.07e−53), and characteristics including CD4 count (P = .003), bacillary load (P = 3.02e−05), lung cavities (P = 1.59e−04), and lung quadrants involved (P = 3.87e−06). The mHR score was not associated with Mtb aerosolization. In total, 105 (50%) participants had PTLD at 12 months including 61 with restriction, 26 with obstruction, and 18 with mixed obstruction and restriction. Baseline mHR was associated with obstructive PTLD at both 6 (P = .003) and 12 months (P = .012) in bivariate and multivariate analyses. The mHR score was not associated with restrictive lung disease. Conclusions: Baseline mHR was associated with obstructive PTLD at 6 and 12 months and may have applications in targeting treatment and prognostication.
- Open Access
- 28 August 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (11) , 2799-2811
HOPE Kids 2: Phase 3, Randomized Trial of Voxelotor in Children With SCD and Conditional Cerebral Blood Flow Velocities
Children with SCD have elevated stroke risk, correlated with cerebral blood flow velocity (CBFV). HOPE Kids 2 was a phase 3, multicenter, double‐blind, placebo‐controlled trial evaluating the effect of voxelotor on CBFV. Participants aged 2 to < 15 years with SCD (HbSS/HbSβ 0 ) and conditional CBFV (170 to < 200 cm/s) were randomized 1:1 to voxelotor ( N = 120) or placebo ( N = 116) for 96 weeks; 195 (83%) were in sub‐Saharan Africa. The primary endpoint, CBFV change from baseline to Week 24, was significantly greater with voxelotor (least‐squares mean change: voxelotor [ n = 114] −12.06 cm/s, placebo [ n = 108] −4.29 cm/s; difference −7.77 cm/s; 95% CI −13.18 to −2.37; p = 0.0048), with significant difference sustained through Week 48. Hemoglobin levels increased at Weeks 24 and 48 with voxelotor. Drug administration was paused in May 2024 when an imbalance of deaths was observed between treatment groups; subsequently, the trial discontinued when all active voxelotor trials were discontinued in September 2024. At study end, median (range) exposure was 84 (3–104) weeks for voxelotor and 84 (3–106) weeks for placebo. The most common SCD‐related treatment‐emergent adverse event was sickle cell anemia with crisis (voxelotor 59.2%; placebo 37.9%). All deaths (voxelotor n = 8; placebo n = 2) were considered unrelated to study drug by treating investigators. Overall, voxelotor showed CBFV reduction in children with SCD and conditional CBFV, suggesting HbS polymerization inhibition has a potential therapeutic role for this group; nevertheless, additional studies evaluating potential regional risks for sickle cell anemia with crisis or mortality are warranted. Trial Registration: ClinicalTrials.gov identifier: NCT04218084
- 28 August 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (11) , 2799-2811
Open AccessHOPE Kids 2: Phase 3, Randomized Trial of Voxelotor in Children With SCD and Conditional Cerebral Blood Flow Velocities
Children with SCD have elevated stroke risk, correlated with cerebral blood flow velocity (CBFV). HOPE Kids 2 was a phase 3, multicenter, double‐blind, placebo‐controlled trial evaluating the effect of voxelotor on CBFV. Participants aged 2 to < 15 years with SCD (HbSS/HbSβ 0 ) and conditional CBFV (170 to < 200 cm/s) were randomized 1:1 to voxelotor ( N = 120) or placebo ( N = 116) for 96 weeks; 195 (83%) were in sub‐Saharan Africa. The primary endpoint, CBFV change from baseline to Week 24, was significantly greater with voxelotor (least‐squares mean change: voxelotor [ n = 114] −12.06 cm/s, placebo [ n = 108] −4.29 cm/s; difference −7.77 cm/s; 95% CI −13.18 to −2.37; p = 0.0048), with significant difference sustained through Week 48. Hemoglobin levels increased at Weeks 24 and 48 with voxelotor. Drug administration was paused in May 2024 when an imbalance of deaths was observed between treatment groups; subsequently, the trial discontinued when all active voxelotor trials were discontinued in September 2024. At study end, median (range) exposure was 84 (3–104) weeks for voxelotor and 84 (3–106) weeks for placebo. The most common SCD‐related treatment‐emergent adverse event was sickle cell anemia with crisis (voxelotor 59.2%; placebo 37.9%). All deaths (voxelotor n = 8; placebo n = 2) were considered unrelated to study drug by treating investigators. Overall, voxelotor showed CBFV reduction in children with SCD and conditional CBFV, suggesting HbS polymerization inhibition has a potential therapeutic role for this group; nevertheless, additional studies evaluating potential regional risks for sickle cell anemia with crisis or mortality are warranted. Trial Registration: ClinicalTrials.gov identifier: NCT04218084
- Open Access
- 28 August 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Genetic Characterization of M. tuberculosis Isolates From Participants in a Phase 2b Randomized Trial Evaluating the M72/AS01E Tuberculosis Candidate Vaccine
Background: The efficacy and safety of the M72/AS01E tuberculosis (TB) candidate vaccine were evaluated in the phase 2b randomized, placebo-controlled trial NCT01755598. In the trial, participants with Mycobacterium tuberculosis sensitization by a positive interferon-gamma release assay received either M72/AS01E or placebo (randomized 1:1) and were followed for 3 years. In this descriptive study, we genetically characterized M. tuberculosis isolates from participants who developed pulmonary TB during the trial to assess variability among isolates and evaluate the possibility of preferential progression from infection to active TB by certain strains in M72/AS01E and placebo recipients. Methods: M. tuberculosis isolates were recovered from sputum samples and underwent DNA extraction and sequencing to assess lineage, antibiotic resistance profile, genetic variation, and genomic clusters. Results: One hundred isolates (37 M72/AS01E, 63 placebo) were genetically characterized from 50 participants who developed microbiologically confirmed active pulmonary TB during the trial (20 M72/AS01E, 30 placebo). Diverse M. tuberculosis lineages were identified in both M72/AS01E and placebo recipients. No multidrug-resistant strains were detected. Genetic sequences corresponding to the antigenic components of M72/AS01E showed low variation in pepA and high variation in PPE18. However, no apparent preferential distribution of variants was observed in M72/AS01E or placebo recipients. Cluster analyses identified 10 genomic clusters with isolates from >1 participant, illustrating complex transmission dynamics and potential of coinfection by multiple strains within individuals. Conclusions: This descriptive analysis showed no apparent preferential distribution of local M. tuberculosis strains in M72/AS01E or placebo recipients. These results support the continued development of this candidate vaccine. Clinical Trials Registration: The NCT01755598 study was registered at https://Cinicaltrials.gov on 19 December 2012. The trial protocol and statistical analysis plan can be accessed from the trial registration website https://clinicaltrials.gov/study/NCT01755598.
- 28 August 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Open AccessGenetic Characterization of M. tuberculosis Isolates From Participants in a Phase 2b Randomized Trial Evaluating the M72/AS01E Tuberculosis Candidate Vaccine
Background: The efficacy and safety of the M72/AS01E tuberculosis (TB) candidate vaccine were evaluated in the phase 2b randomized, placebo-controlled trial NCT01755598. In the trial, participants with Mycobacterium tuberculosis sensitization by a positive interferon-gamma release assay received either M72/AS01E or placebo (randomized 1:1) and were followed for 3 years. In this descriptive study, we genetically characterized M. tuberculosis isolates from participants who developed pulmonary TB during the trial to assess variability among isolates and evaluate the possibility of preferential progression from infection to active TB by certain strains in M72/AS01E and placebo recipients. Methods: M. tuberculosis isolates were recovered from sputum samples and underwent DNA extraction and sequencing to assess lineage, antibiotic resistance profile, genetic variation, and genomic clusters. Results: One hundred isolates (37 M72/AS01E, 63 placebo) were genetically characterized from 50 participants who developed microbiologically confirmed active pulmonary TB during the trial (20 M72/AS01E, 30 placebo). Diverse M. tuberculosis lineages were identified in both M72/AS01E and placebo recipients. No multidrug-resistant strains were detected. Genetic sequences corresponding to the antigenic components of M72/AS01E showed low variation in pepA and high variation in PPE18. However, no apparent preferential distribution of variants was observed in M72/AS01E or placebo recipients. Cluster analyses identified 10 genomic clusters with isolates from >1 participant, illustrating complex transmission dynamics and potential of coinfection by multiple strains within individuals. Conclusions: This descriptive analysis showed no apparent preferential distribution of local M. tuberculosis strains in M72/AS01E or placebo recipients. These results support the continued development of this candidate vaccine. Clinical Trials Registration: The NCT01755598 study was registered at https://Cinicaltrials.gov on 19 December 2012. The trial protocol and statistical analysis plan can be accessed from the trial registration website https://clinicaltrials.gov/study/NCT01755598.
- Open Access
- 1 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7)
Associations Between QuantiFERON-TB Gold Plus IFNγ Concentrations and Progression to Symptomatic Tuberculosis in Global High-Burden TB Settings
Background: Predictive biomarkers for symptomatic tuberculosis (TB) progression would transform targeted prevention efforts. Although interferon-gamma release assays (IGRAs), including QuantiFERON® TB-Gold Plus (QFT-Plus), have been studied for this purpose, systematic evaluation of the QFT-Plus TB1 and TB2 Interferon-Gamma (IFNγ) concentrations remains limited, particularly in high-burden TB settings. Methods: Baseline TB1 and TB2 IFNγ concentrations from 5246 participants (ages 15–34 years) in TB-endemic regions were analyzed in relation to subsequent TB outcomes over a median of 525 days follow-up (NCT05190146). Participants were categorized as controls (no TB), suspected TB (no microbiological confirmation), or laboratory-confirmed TB, including a subset meeting a stringent case definition (≥2 positive microbiologic tests). Associations between baseline IFNγ concentrations and progression to symptomatic TB were assessed. Results: In the full cohort (IGRA+/− participants), baseline TB2 IFNγ concentrations were significantly higher compared with controls among participants who developed suspected TB (P = .01), laboratory-confirmed TB (P = .01), or met the stringent case definition (P < .0001). In IGRA+ participants, baseline TB2 concentrations were significantly higher than controls in suspected (P = .01) and laboratory-confirmed (P = .02) groups. Associations with baseline TB1 IFNγ concentrations and TB progression were observed for participants meeting the stringent case definition within the full cohort (P = .001). Among stringent definition cases, TB2 concentrations achieved an area under the receiver operating characteristic curve of 0.84, with sensitivity of 80% and specificity of 78%. Conclusions: Quantitative IFNγ concentrations from QFT-Plus, particularly TB2, were associated with progression to symptomatic TB, met or exceeded WHO-recommended sensitivity and specificity thresholds for predictive biomarkers, and may support biomarker-based stratification in TB clinical research.
- 1 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7)
Open AccessAssociations Between QuantiFERON-TB Gold Plus IFNγ Concentrations and Progression to Symptomatic Tuberculosis in Global High-Burden TB Settings
Background: Predictive biomarkers for symptomatic tuberculosis (TB) progression would transform targeted prevention efforts. Although interferon-gamma release assays (IGRAs), including QuantiFERON® TB-Gold Plus (QFT-Plus), have been studied for this purpose, systematic evaluation of the QFT-Plus TB1 and TB2 Interferon-Gamma (IFNγ) concentrations remains limited, particularly in high-burden TB settings. Methods: Baseline TB1 and TB2 IFNγ concentrations from 5246 participants (ages 15–34 years) in TB-endemic regions were analyzed in relation to subsequent TB outcomes over a median of 525 days follow-up (NCT05190146). Participants were categorized as controls (no TB), suspected TB (no microbiological confirmation), or laboratory-confirmed TB, including a subset meeting a stringent case definition (≥2 positive microbiologic tests). Associations between baseline IFNγ concentrations and progression to symptomatic TB were assessed. Results: In the full cohort (IGRA+/− participants), baseline TB2 IFNγ concentrations were significantly higher compared with controls among participants who developed suspected TB (P = .01), laboratory-confirmed TB (P = .01), or met the stringent case definition (P < .0001). In IGRA+ participants, baseline TB2 concentrations were significantly higher than controls in suspected (P = .01) and laboratory-confirmed (P = .02) groups. Associations with baseline TB1 IFNγ concentrations and TB progression were observed for participants meeting the stringent case definition within the full cohort (P = .001). Among stringent definition cases, TB2 concentrations achieved an area under the receiver operating characteristic curve of 0.84, with sensitivity of 80% and specificity of 78%. Conclusions: Quantitative IFNγ concentrations from QFT-Plus, particularly TB2, were associated with progression to symptomatic TB, met or exceeded WHO-recommended sensitivity and specificity thresholds for predictive biomarkers, and may support biomarker-based stratification in TB clinical research.
- Open Access
A whole-blood transcriptional signature associated with obstructive post-tuberculosis lung disease
Background: Post-tuberculosis (TB) lung disease (PTLD) affects approximately 50% of persons with pulmonary TB. We recently discovered whole blood transcriptional signatures associated with PTLD. We examined whether a minimum gene signature predicts PTLD as a clinically useful biomarker. Methods: We prospectively enrolled 301 treatment naïve adults with newly diagnosed pulmonary TB (PTB) (cohort A). We collected whole blood at 0 and 6-month visits, isolated RNA, and measured a modified MTB Host Response (HR) signature (mHR) based on expression of DUSP3, GBP5, and TMBIM6. We recorded spirometry at 6 (n=216) and 12 months (n=210) after treatment initiation and examined the association of the mHR score with PTLD and Mtb aerosolization. We recruited household contacts of cohort A to compare mHR score with non-PTB participants (cohort B). Findings: mHR was associated with TB (p=4.15e-66) when compared to HHCs, treatment response (p=1.07e-53), and characteristics including CD4 count (p=0.003), bacillary load (p=3.02e-05), lung cavities (p=1.59e-04), and lung quadrants involved (p=3.87e-06). The mHR score was not associated with Mtb aerosolization. In total, 105 (50%) participants had PTLD at 12 months including 61 with restriction, 26 with obstruction, and 18 with mixed obstruction and restriction. Baseline mHR was associated with obstructive PTLD at both 6 (p=0.003) and 12 months (p=0.012) in bivariate and multivariate analyses. The mHR score was not associated with restrictive lung disease. Interpretation: Baseline mHR was associated with obstructive PTLD at 6 and 12 months and may have applications in targeting treatment and prognostication.
Open AccessA whole-blood transcriptional signature associated with obstructive post-tuberculosis lung disease
Background: Post-tuberculosis (TB) lung disease (PTLD) affects approximately 50% of persons with pulmonary TB. We recently discovered whole blood transcriptional signatures associated with PTLD. We examined whether a minimum gene signature predicts PTLD as a clinically useful biomarker. Methods: We prospectively enrolled 301 treatment naïve adults with newly diagnosed pulmonary TB (PTB) (cohort A). We collected whole blood at 0 and 6-month visits, isolated RNA, and measured a modified MTB Host Response (HR) signature (mHR) based on expression of DUSP3, GBP5, and TMBIM6. We recorded spirometry at 6 (n=216) and 12 months (n=210) after treatment initiation and examined the association of the mHR score with PTLD and Mtb aerosolization. We recruited household contacts of cohort A to compare mHR score with non-PTB participants (cohort B). Findings: mHR was associated with TB (p=4.15e-66) when compared to HHCs, treatment response (p=1.07e-53), and characteristics including CD4 count (p=0.003), bacillary load (p=3.02e-05), lung cavities (p=1.59e-04), and lung quadrants involved (p=3.87e-06). The mHR score was not associated with Mtb aerosolization. In total, 105 (50%) participants had PTLD at 12 months including 61 with restriction, 26 with obstruction, and 18 with mixed obstruction and restriction. Baseline mHR was associated with obstructive PTLD at both 6 (p=0.003) and 12 months (p=0.012) in bivariate and multivariate analyses. The mHR score was not associated with restrictive lung disease. Interpretation: Baseline mHR was associated with obstructive PTLD at 6 and 12 months and may have applications in targeting treatment and prognostication.
- Open Access
- 18 February 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (2) , e0003849
Persistently high TB prevalence in Nairobi County neighbourhoods, 2015–2022
National and sub-national population-based surveys, when performed at intervals, may assess important changes in TB prevalence. In 2022 we re-surveyed nine Nairobi County neighbourhoods that were previously surveyed in 2015. We aimed to determine pulmonary TB prevalence, compare prevalence to 2015 estimates, and evaluate changes in risk groups. Participants who reported cough of any duration and/or whose chest x-ray suggested TB submitted sputum for smear microscopy, Xpert Ultra, and liquid culture. We defined prevalent TB as Mycobacterium tuberculosis detection by sputum Xpert or culture, excepting individuals who were only trace positive. Our methods differed from 2015, which used solid media, Xpert MTB/RIF, and cough duration >2 weeks. We calculated TB prevalence using random-effects logistic regression models with missing value imputations and inverse probability weighting. In 2022 among 6369 participants, 1582 submitted ≥1 sputum sample, among whom 42 (2.7%) had TB, a weighted TB prevalence of 806/100,000 (95% confidence interval (CI), 518–1096). An additional 31 (2.0%) participants tested Ultra trace-positive/culture-negative. For comparison to 2015, we excluded 2022 participants (n = 2) whose only criterion for sputum was cough <2 weeks. There was no evidence for a decline in overall TB prevalence from 2015 to 2022. TB prevalence among men was high (1301/100,000) and remained high compared to 2015 (p-value <0.05). The age group with the highest estimated prevalence remained people ages 45–54 years. Among people with prevalent TB who reported cough, 76% had not sought health care. Dissimilar from other serial surveys that showed declines in TB prevalence, we found persistently high TB prevalence over a 7-year period in Nairobi County. Limitations of this study include changes in methodology between the two surveys and complex effects of the COVID-19 pandemic.
- 18 February 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (2) , e0003849
Open AccessPersistently high TB prevalence in Nairobi County neighbourhoods, 2015–2022
National and sub-national population-based surveys, when performed at intervals, may assess important changes in TB prevalence. In 2022 we re-surveyed nine Nairobi County neighbourhoods that were previously surveyed in 2015. We aimed to determine pulmonary TB prevalence, compare prevalence to 2015 estimates, and evaluate changes in risk groups. Participants who reported cough of any duration and/or whose chest x-ray suggested TB submitted sputum for smear microscopy, Xpert Ultra, and liquid culture. We defined prevalent TB as Mycobacterium tuberculosis detection by sputum Xpert or culture, excepting individuals who were only trace positive. Our methods differed from 2015, which used solid media, Xpert MTB/RIF, and cough duration >2 weeks. We calculated TB prevalence using random-effects logistic regression models with missing value imputations and inverse probability weighting. In 2022 among 6369 participants, 1582 submitted ≥1 sputum sample, among whom 42 (2.7%) had TB, a weighted TB prevalence of 806/100,000 (95% confidence interval (CI), 518–1096). An additional 31 (2.0%) participants tested Ultra trace-positive/culture-negative. For comparison to 2015, we excluded 2022 participants (n = 2) whose only criterion for sputum was cough <2 weeks. There was no evidence for a decline in overall TB prevalence from 2015 to 2022. TB prevalence among men was high (1301/100,000) and remained high compared to 2015 (p-value <0.05). The age group with the highest estimated prevalence remained people ages 45–54 years. Among people with prevalent TB who reported cough, 76% had not sought health care. Dissimilar from other serial surveys that showed declines in TB prevalence, we found persistently high TB prevalence over a 7-year period in Nairobi County. Limitations of this study include changes in methodology between the two surveys and complex effects of the COVID-19 pandemic.
- Open Access
Persistently high TB prevalence in Nairobi County neighbourhoods, 2015-2022
National and sub-national population-based surveys, when performed at intervals, may assess important changes in TB prevalence. In 2022 we re-surveyed nine Nairobi County neighbourhoods that were previously surveyed in 2015. We aimed to determine pulmonary TB prevalence, compare prevalence to 2015 estimates, and evaluate changes in risk groups. Participants who reported cough of any duration and/or whose chest x-ray suggested TB submitted sputum for smear microscopy, Xpert Ultra, and liquid culture. We defined prevalent TB as Mycobacterium tuberculosis detection by sputum Xpert or culture, excepting individuals who were only trace positive. Our methods differed from 2015, which used solid media, Xpert MTB/RIF, and cough duration >2 weeks. We calculated TB prevalence using random-effects logistic regression models with missing value imputations and inverse probability weighting. In 2022 among 6369 participants, 1582 submitted >1 sputum sample, among whom 42 (2·7%) had TB, a weighted TB prevalence of 806/100,000 (95% confidence interval (CI), 518-1096). An additional 31 (2·0%) participants tested Ultra trace-positive/culture-negative. For comparison to 2015, we excluded 2022 participants (n=2) whose only criterion for sputum was cough <2 weeks. There was no evidence for a decline in overall TB prevalence from 2015 to 2022. TB prevalence among men was high (1368/100,000) but unchanged compared to 2015 (p-value = 0·50). The age group with the highest estimated prevalence remained people ages 45–54 years. Among people with prevalent TB who reported cough, 76% had not sought health care. Dissimilar from other serial surveys that showed declines in TB prevalence, we found persistently high TB prevalence over a 7-year period in Nairobi County. Limitations of this study include changes in methodology between the two surveys and complex effects of the COVID-19 pandemic.
Open AccessPersistently high TB prevalence in Nairobi County neighbourhoods, 2015-2022
National and sub-national population-based surveys, when performed at intervals, may assess important changes in TB prevalence. In 2022 we re-surveyed nine Nairobi County neighbourhoods that were previously surveyed in 2015. We aimed to determine pulmonary TB prevalence, compare prevalence to 2015 estimates, and evaluate changes in risk groups. Participants who reported cough of any duration and/or whose chest x-ray suggested TB submitted sputum for smear microscopy, Xpert Ultra, and liquid culture. We defined prevalent TB as Mycobacterium tuberculosis detection by sputum Xpert or culture, excepting individuals who were only trace positive. Our methods differed from 2015, which used solid media, Xpert MTB/RIF, and cough duration >2 weeks. We calculated TB prevalence using random-effects logistic regression models with missing value imputations and inverse probability weighting. In 2022 among 6369 participants, 1582 submitted >1 sputum sample, among whom 42 (2·7%) had TB, a weighted TB prevalence of 806/100,000 (95% confidence interval (CI), 518-1096). An additional 31 (2·0%) participants tested Ultra trace-positive/culture-negative. For comparison to 2015, we excluded 2022 participants (n=2) whose only criterion for sputum was cough <2 weeks. There was no evidence for a decline in overall TB prevalence from 2015 to 2022. TB prevalence among men was high (1368/100,000) but unchanged compared to 2015 (p-value = 0·50). The age group with the highest estimated prevalence remained people ages 45–54 years. Among people with prevalent TB who reported cough, 76% had not sought health care. Dissimilar from other serial surveys that showed declines in TB prevalence, we found persistently high TB prevalence over a 7-year period in Nairobi County. Limitations of this study include changes in methodology between the two surveys and complex effects of the COVID-19 pandemic.
- Open Access
Prevalence and predictors of tuberculosis infection among people living with HIV in a high tuberculosis burden context
Background: Tuberculosis (TB) disease is the leading cause of mortality among people living with the Human immunodeficiency virus (PLHIV). Interferon-gamma release assays (IGRAs) are approved for TB infection ascertainment. However, current IGRA data on the prevalence of TB infection in the context of near-universal access to antiretroviral therapy (ART) and widespread TB preventive therapy (TPT) implementation are lacking. We estimated the prevalence and determinants of TB infection among PLHIV within a high TB and HIV burden context. Methods: This cross-sectional study included data from adult PLHIV age ≥ 18 years in whom QuantiFERON-TB Gold Plus (QFT-Plus) assay, an IGRA, was performed. TB infection was defined as a positive or indeterminate QFT-Plus test. Participants with TB and those who had previously used TPT were excluded. Regression analysis was performed to identify independent predictors of TB infection. Results: Of 121 PLHIV with QFT-Plus test results, females were 74.4% (90/121), and the mean age was 38.4 (standard deviation [SD] 10.8) years. Overall, 47.9% (58/121) were classified as TB infection (QFT-Plus test positive and indeterminate results were 39.7% [48/121] and 8.3% [10/121], respectively), with mean ages of 38.7 (SD 10.30) vs 38.2 (SD 11.3) years, respectively (p=0.602). Being obese/overweight (body mass index ≥25; p=0.013, adjusted odds ratio (aOR) 2.90, 95% confidence interval [CI] 1.25–6.74) and ART usage for >3 years (p=0.013, aOR 3.99, 95% CI 1.55– 10.28) were independently associated with TB infection. Conclusion: There was a high TB infection prevalence among PLHIV. A longer period of ART and obesity were independently associated with TB infection. The relationship between obesity/overweight and TB infection may be related to ART and immune reconstitution and requires further investigation. Given the known benefit of test-directed TPT among PLHIV never exposed to TPT, its clinical and cost implications for low and middle-income countries should be explored further. KEY MESSAGES: What is already known on this topic: Among people living with HIV (PLHIV), the risk of progression to tuberculosis (TB) disease is higher with confirmed and untreated TB infection. Data on the prevalence of TB infection in the context of near-universal access to antiretroviral therapy (ART) and widespread TB preventive therapy (TPT) implementation are lacking in Africa. What this study adds: This study provides evidence that the prevalence of TB infection remains high even in the context of near-universal ART and widespread TPT. ART use and obesity/overweight may be associated with TB infection. How this study might affect research, practice or policy: This study should prompt larger studies to explore predictors of TB infection. TPT should remain as part of care for PLHIV on ART. A broader understanding of the clinical and cost implications of test-directed TPT for PLHIV in low and middle-income countries may better inform policy towards its recommendation.
Open AccessPrevalence and predictors of tuberculosis infection among people living with HIV in a high tuberculosis burden context
Background: Tuberculosis (TB) disease is the leading cause of mortality among people living with the Human immunodeficiency virus (PLHIV). Interferon-gamma release assays (IGRAs) are approved for TB infection ascertainment. However, current IGRA data on the prevalence of TB infection in the context of near-universal access to antiretroviral therapy (ART) and widespread TB preventive therapy (TPT) implementation are lacking. We estimated the prevalence and determinants of TB infection among PLHIV within a high TB and HIV burden context. Methods: This cross-sectional study included data from adult PLHIV age ≥ 18 years in whom QuantiFERON-TB Gold Plus (QFT-Plus) assay, an IGRA, was performed. TB infection was defined as a positive or indeterminate QFT-Plus test. Participants with TB and those who had previously used TPT were excluded. Regression analysis was performed to identify independent predictors of TB infection. Results: Of 121 PLHIV with QFT-Plus test results, females were 74.4% (90/121), and the mean age was 38.4 (standard deviation [SD] 10.8) years. Overall, 47.9% (58/121) were classified as TB infection (QFT-Plus test positive and indeterminate results were 39.7% [48/121] and 8.3% [10/121], respectively), with mean ages of 38.7 (SD 10.30) vs 38.2 (SD 11.3) years, respectively (p=0.602). Being obese/overweight (body mass index ≥25; p=0.013, adjusted odds ratio (aOR) 2.90, 95% confidence interval [CI] 1.25–6.74) and ART usage for >3 years (p=0.013, aOR 3.99, 95% CI 1.55– 10.28) were independently associated with TB infection. Conclusion: There was a high TB infection prevalence among PLHIV. A longer period of ART and obesity were independently associated with TB infection. The relationship between obesity/overweight and TB infection may be related to ART and immune reconstitution and requires further investigation. Given the known benefit of test-directed TPT among PLHIV never exposed to TPT, its clinical and cost implications for low and middle-income countries should be explored further. KEY MESSAGES: What is already known on this topic: Among people living with HIV (PLHIV), the risk of progression to tuberculosis (TB) disease is higher with confirmed and untreated TB infection. Data on the prevalence of TB infection in the context of near-universal access to antiretroviral therapy (ART) and widespread TB preventive therapy (TPT) implementation are lacking in Africa. What this study adds: This study provides evidence that the prevalence of TB infection remains high even in the context of near-universal ART and widespread TPT. ART use and obesity/overweight may be associated with TB infection. How this study might affect research, practice or policy: This study should prompt larger studies to explore predictors of TB infection. TPT should remain as part of care for PLHIV on ART. A broader understanding of the clinical and cost implications of test-directed TPT for PLHIV in low and middle-income countries may better inform policy towards its recommendation.
- Open Access
- 1 January 2022
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 6 (Suppl) , 9-10
S118: LONG-TERM SAFETY AND EFFICACY OF VOXELOTOR FOR PATIENTS WITH SICKLE CELL DISEASE: RESULTS FROM AN OPEN-LABEL EXTENSION OF THE PHASE 3 HOPE TRIAL
- 1 January 2022
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 6 (Suppl) , 9-10
Open AccessS118: LONG-TERM SAFETY AND EFFICACY OF VOXELOTOR FOR PATIENTS WITH SICKLE CELL DISEASE: RESULTS FROM AN OPEN-LABEL EXTENSION OF THE PHASE 3 HOPE TRIAL
- Open Access
- 1 January 2014
- Published by Wiley in Interdisciplinary Perspectives on Infectious Diseases
- Vol. 2014, 1-8
Chest Radiographs for Pediatric TB Diagnosis: Interrater Agreement and Utility
The chest radiograph (CXR) is considered a key diagnostic tool for pediatric tuberculosis (TB) in clinical management and endpoint determination in TB vaccine trials. We set out to compare interrater agreement for TB diagnosis in western Kenya. A pediatric pulmonologist and radiologist (experts), a medical officer (M.O), and four clinical officers (C.Os) with basic training in pediatric CXR reading blindly assessed CXRs of infants who were TB suspects in a cohort study. C.Os had access to clinical findings for patient management. Weighted kappa scores summarized interrater agreement on lymphadenopathy and abnormalities consistent with TB. Sensitivity and specificity of raters were determined using microbiologically confirmed TB as the gold standard. A total of 691 radiographs were reviewed. Agreement on abnormalities consistent with TB was poor;(95% CI: 0.10–0.18) and on lymphadenopathy moderate(95% CI: 0.18–0.36). M.O [75% (95% CI: 34.9%–96.8%)] and C.Os [63% (95% CI: 24.5%–91.5%)] had high sensitivity for culture confirmed TB. TB vaccine trials utilizing expert agreement on CXR as a nonmicrobiologically confirmed endpoint will have reduced specificity and will underestimate vaccine efficacy. C.Os detected many of the bacteriologically confirmed cases; however, this must be interpreted cautiously as they were unblinded to clinical features.- 1 January 2014
- Published by Wiley in Interdisciplinary Perspectives on Infectious Diseases
- Vol. 2014, 1-8
Open AccessChest Radiographs for Pediatric TB Diagnosis: Interrater Agreement and Utility
The chest radiograph (CXR) is considered a key diagnostic tool for pediatric tuberculosis (TB) in clinical management and endpoint determination in TB vaccine trials. We set out to compare interrater agreement for TB diagnosis in western Kenya. A pediatric pulmonologist and radiologist (experts), a medical officer (M.O), and four clinical officers (C.Os) with basic training in pediatric CXR reading blindly assessed CXRs of infants who were TB suspects in a cohort study. C.Os had access to clinical findings for patient management. Weighted kappa scores summarized interrater agreement on lymphadenopathy and abnormalities consistent with TB. Sensitivity and specificity of raters were determined using microbiologically confirmed TB as the gold standard. A total of 691 radiographs were reviewed. Agreement on abnormalities consistent with TB was poor;(95% CI: 0.10–0.18) and on lymphadenopathy moderate(95% CI: 0.18–0.36). M.O [75% (95% CI: 34.9%–96.8%)] and C.Os [63% (95% CI: 24.5%–91.5%)] had high sensitivity for culture confirmed TB. TB vaccine trials utilizing expert agreement on CXR as a nonmicrobiologically confirmed endpoint will have reduced specificity and will underestimate vaccine efficacy. C.Os detected many of the bacteriologically confirmed cases; however, this must be interpreted cautiously as they were unblinded to clinical features.